Please see attached letter from LEO Pharma in relation to Picato (ingenol mebutate) - Suspension of the marketing authorisation due to risk of skin malignancy.
Picato - update 29.01.20
(Picato.pdf | 428 KB)
Visit our Clinical Hub ยป
